MX377622B - Suspensión que comprende hidróxido de aluminio e hidróxido de magnesio y método de preparación de la misma. - Google Patents

Suspensión que comprende hidróxido de aluminio e hidróxido de magnesio y método de preparación de la misma.

Info

Publication number
MX377622B
MX377622B MX2019012084A MX2019012084A MX377622B MX 377622 B MX377622 B MX 377622B MX 2019012084 A MX2019012084 A MX 2019012084A MX 2019012084 A MX2019012084 A MX 2019012084A MX 377622 B MX377622 B MX 377622B
Authority
MX
Mexico
Prior art keywords
hydroxide
aluminum hydroxide
magnesium hydroxide
present
aqueous suspension
Prior art date
Application number
MX2019012084A
Other languages
English (en)
Other versions
MX2019012084A (es
Inventor
Chao Tong
Qing Ri Li
Sang Ho Seol
Tie Li
Ye Chang
Original Assignee
Daewoong Pharmaceutical Co Ltd
Liaoning Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd, Liaoning Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of MX2019012084A publication Critical patent/MX2019012084A/es
Publication of MX377622B publication Critical patent/MX377622B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

La presente invención proporciona una suspensión que comprende hidróxido de aluminio e hidróxido de magnesio y un método de preparación de la misma. La composición de suspensión acuosa de acuerdo con la presente invención garantiza una excelente velocidad de sedimentación mediante el uso de un agente de suspensión mixto con una composición específica, de manera que el hidróxido de aluminio y el hidróxido de magnesio insolubles no se sedimenten fácilmente, no formen una torta y se redispersen fácilmente. Puesto que la composición de suspensión acuosa que tiene una excelente velocidad de sedimentación no solo tiene estabilidad física, sino que también forma un sistema de dispersión homogéneo, puede garantizarse la reproducibilidad o eficacia de la biodisponibilidad. Además, la composición de suspensión acuosa de acuerdo con la presente invención proporciona una textura excelente y, por tanto, el cumplimiento del paciente aumenta.
MX2019012084A 2017-04-13 2018-04-12 Suspensión que comprende hidróxido de aluminio e hidróxido de magnesio y método de preparación de la misma. MX377622B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710240597.0A CN108721213A (zh) 2017-04-13 2017-04-13 铝镁混悬液及其制备方法
PCT/KR2018/004305 WO2018190659A1 (ko) 2017-04-13 2018-04-12 수산화알루미늄과 수산화마그네슘을 포함하는 현탁액 및 그 제조방법

Publications (2)

Publication Number Publication Date
MX2019012084A MX2019012084A (es) 2020-01-20
MX377622B true MX377622B (es) 2025-03-10

Family

ID=63793453

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012084A MX377622B (es) 2017-04-13 2018-04-12 Suspensión que comprende hidróxido de aluminio e hidróxido de magnesio y método de preparación de la misma.

Country Status (15)

Country Link
US (1) US11135165B2 (es)
EP (1) EP3610857B1 (es)
JP (1) JP7090641B2 (es)
KR (1) KR102396359B1 (es)
CN (2) CN108721213A (es)
AU (1) AU2018251519B2 (es)
CA (1) CA3059031C (es)
CO (1) CO2019012413A2 (es)
ES (1) ES2908336T3 (es)
MX (1) MX377622B (es)
PH (1) PH12019502323B1 (es)
PL (1) PL3610857T3 (es)
SA (1) SA519410276B1 (es)
WO (1) WO2018190659A1 (es)
ZA (1) ZA201906662B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108721213A (zh) 2017-04-13 2018-11-02 辽宁大熊制药有限公司 铝镁混悬液及其制备方法
CN114028331B (zh) * 2021-11-03 2022-11-18 北京鑫开元医药科技有限公司 镁加铝混悬液及其制备工艺
KR102788240B1 (ko) * 2023-01-17 2025-04-01 주식회사 금강건설 야간 시인성이 향상된 노면표지용 도료 조성물
CN117159461A (zh) * 2023-07-26 2023-12-05 合肥远志医药科技开发有限公司 一种铝碳酸镁混悬液及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3272704A (en) 1963-06-06 1966-09-13 Armour Pharma Stable aluminum hydroxide-magnesium compound codried gel antacids and process of making the same
US3591680A (en) * 1969-11-17 1971-07-06 Smith Kline French Lab Concentrated antacid compositions and method of producing antacid activity
US4443433A (en) 1981-11-13 1984-04-17 Warner-Lambert Company Antacid material based on magnesium aluminum hydroxide and preparation thereof
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
US5593489A (en) 1995-10-20 1997-01-14 Ecc International Inc. Acid resistant carbonate composition containing an aluminum or magnesium hydroxide methods of preparation and uses therefor
US5914135A (en) * 1997-04-16 1999-06-22 Mcneil-Ppc, Inc. Liquid antacid compositions
AU4759099A (en) * 1998-09-21 2000-03-23 Mcneil-Ppc, Inc. Heat stable antacid and antigas suspensions
KR20000046974A (ko) * 1998-12-31 2000-07-25 윤재승 아세글루타미드 알루미늄의 경구 투여용 제제 조성물ㅇ
US20030232092A1 (en) * 2002-06-14 2003-12-18 Hasenmayer Donald L. Liquid antacid compositions
MY151468A (en) * 2005-12-28 2014-05-30 Takeda Pharmaceutical Controlled release solid preparation
CN101002939A (zh) * 2007-01-12 2007-07-25 广东华南药业有限公司 一类治疗与胃酸有关疾病的药物组合制剂
CN101002769A (zh) * 2007-01-12 2007-07-25 广东华南药业有限公司 奥美拉唑组合物制剂
US20130243888A1 (en) * 2010-07-27 2013-09-19 Sara Beth Ford Composition and Method for the Topical Treatment of Dermatitis
CN102319208A (zh) * 2011-09-23 2012-01-18 何雪心 一种治疗化放疗所致口腔黏膜炎的悬浮液组合物
CN104173372A (zh) * 2014-09-03 2014-12-03 左克源 治疗口腔粘膜炎的组合物及其制备方法与应用包装
CN105853352B (zh) * 2016-05-19 2018-12-25 武汉先路医药科技股份有限公司 一种含有普拉洛芬的混悬液处方组成及其制备方法
CN108721213A (zh) 2017-04-13 2018-11-02 辽宁大熊制药有限公司 铝镁混悬液及其制备方法

Also Published As

Publication number Publication date
JP2020516660A (ja) 2020-06-11
ES2908336T3 (es) 2022-04-28
PH12019502323A1 (en) 2020-07-06
CN109414406B (zh) 2019-12-13
WO2018190659A1 (ko) 2018-10-18
MX2019012084A (es) 2020-01-20
JP7090641B2 (ja) 2022-06-24
US11135165B2 (en) 2021-10-05
PL3610857T3 (pl) 2022-06-20
CN109414406A (zh) 2019-03-01
EP3610857A1 (en) 2020-02-19
RU2019131244A (ru) 2021-04-05
AU2018251519B2 (en) 2023-06-15
EP3610857A4 (en) 2020-09-16
CO2019012413A2 (es) 2020-01-17
US20200113826A1 (en) 2020-04-16
AU2018251519A1 (en) 2019-11-14
ZA201906662B (en) 2021-06-30
PH12019502323B1 (en) 2020-07-06
RU2019131244A3 (es) 2021-06-30
CA3059031A1 (en) 2018-10-18
EP3610857B1 (en) 2022-02-09
CN108721213A (zh) 2018-11-02
KR102396359B1 (ko) 2022-05-10
CA3059031C (en) 2022-08-16
BR112019021477A2 (pt) 2020-05-12
SA519410276B1 (ar) 2024-01-30
KR20190130590A (ko) 2019-11-22

Similar Documents

Publication Publication Date Title
WO2017066256A3 (en) Compositions and methods for viral cancer neoepitopes
PH12019502323A1 (en) Suspension comprising aluminum hydroxide and magnesium hydroxide and preparation method therefor
BR112016024644A2 (pt) vacinas de ácido nucleico
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
MX372914B (es) Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo.
MX2016014320A (es) Composiciones de suspension de liberacion prolongada.
TW201613859A (en) Analogs of PRIDOPIDINE, their preparation and use
WO2016001754A3 (en) Methods for three dimensional reconstruction and determining the quality of an embryo
ZA202403393B (en) Synthetic chimeric poxviruses
MX2020003369A (es) Enantiomeros de tiazoles sustituidos como compuestos antivirales.
EP4218790A8 (en) Modulators of complement activity
EP4424374A3 (en) Crystalline forms of tenofovir alafenamide
MX2020000353A (es) Metodos para incubar liquidos e inactivar virus.
BR112018012618A2 (pt) composições da nano emulsão de fluorocarbonos e métodos de preparação e uso dos mesmos
GEAP202115318A (en) Preparation of solid dosage forms comprising antibodies by solution/suspension layering
IN2014CH00840A (es)
EP4424373A3 (en) Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
MX2017015505A (es) Composicion de preparacion solida que contiene pranlukast con biodisponibilidad mejorada y metodo para preparar la misma.
PH12017501869A1 (en) (s)-2'-vinyl-abscisic acid derivatives
MX2020011170A (es) Derivados de 1-imidazotiadiazol-2h-pirrol-5-ona.
WO2017046816A3 (en) Process for the preparation of derivatives of benzodioxole
AU2014232502A8 (en) Process for the preparation of 4-amino-1-((1S,4R, 5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl)-1H-pyrimidin-2-one
MX2018001837A (es) Un proceso mejorado para la preparacion de tetrofosmina o su sal de adicion de acido.

Legal Events

Date Code Title Description
FG Grant or registration